{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:04:44Z","timestamp":1792623884895,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.mcna.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:37:58Z","timestamp":1740757078000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Severe Infections"],"prefix":"10.1016","volume":"109","author":[{"given":"Federico","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim G.","family":"El Chakhtoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mcna.2025.01.003_bib1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"6226","key":"10.1016\/j.mcna.2025.01.003_bib2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.aaa2868","article-title":"Infectious disease. A return to the pre-antimicrobial era?","volume":"347","author":"Baker","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.mcna.2025.01.003_bib3","first-page":"5","article-title":"The discovery of penicillin\u2014new insights after more than 75 Years of clinical use","volume":"23","author":"Gaynes","year":"2017","journal-title":"Emerging Infectious Diseases Journal CDC"},{"issue":"12","key":"10.1016\/j.mcna.2025.01.003_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.7164\/antibiotics.30.1107","article-title":"Piperacillin (T-1220), a new semisynthetic penicillin: in\u00a0vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin","volume":"30","author":"Jones","year":"1977","journal-title":"J\u00a0Antibiot (Tokyo)"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.003_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.003_bib6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/cid\/ciad758","article-title":"The real crisis in antimicrobial resistance: failure to anticipate and respond","volume":"78","author":"Bonomo","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib7","doi-asserted-by":"crossref","first-page":"e02264","DOI":"10.1128\/AAC.02264-19","article-title":"Precision medicine and mysteries in clinical Microbiology: rationalizing epidemiology, genotype, and phenotype to guide therapeutics","volume":"64","author":"Perez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.003_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mcna.2025.01.003_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.003_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3949\/ccjm.80a.12182","article-title":"Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients","volume":"80","author":"Perez","year":"2013","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.003_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.003_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/cid\/ciad288","article-title":"International epidemiology of carbapenemase-producing Escherichia coli","volume":"77","author":"Boutzoukas","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.003_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.003_bib14","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/AAC.01464-06","article-title":"Global challenge of multidrug-resistant Acinetobacter baumannii","volume":"51","author":"Perez","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02759-21","article-title":"Carbapenem-resistant acinetobacter baumannii in U.S. Hospitals: diversification of circulating lineages and antimicrobial resistance","volume":"13","author":"Iovleva","year":"2022","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.003_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00514-21","article-title":"Update on multidrug resistance efflux pumps in acinetobacter spp","volume":"65","author":"Kornelsen","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.003_bib18","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.mcna.2025.01.003_bib19","doi-asserted-by":"crossref","first-page":"E362","DOI":"10.1111\/j.1469-0691.2012.03928.x","article-title":"Dissemination of New Delhi metallo-\u03b2-lactamase-1-producing acinetobacter baumannii in Europe","volume":"18","author":"Bonnin","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.003_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1099\/jmm.0.000289","article-title":"Genetic environment of the KPC gene in Acinetobacter baumannii ST2 clone from Puerto Rico and genomic insights into its drug resistance","volume":"65","author":"Martinez","year":"2016","journal-title":"J\u00a0Med Microbiol"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.003_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0020007","article-title":"Comparative genomics of multidrug resistance in Acinetobacter baumannii","volume":"2","author":"Fournier","year":"2006","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.mcna.2025.01.003_bib22","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-Treat resistance in gram-negative bacteremia at 173\u00a0US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.003_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.003_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03038-22","article-title":"PBP target profiling by \u03b2-lactam and \u03b2-lactamase inhibitors in intact Pseudomonas aeruginosa: effects of the intrinsic and acquired resistance determinants on the periplasmic drug availability","volume":"11","author":"Montaner","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.003_bib25","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.003_bib26","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1128\/AAC.00695-12","article-title":"First report of a Pseudomonas aeruginosa isolate coharboring KPC and VIM carbapenemases","volume":"56","author":"Correa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"Del Barrio-Tofi\u00f1o","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.003_bib28","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.003_bib29","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/jac\/dkae186","article-title":"Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales","volume":"79","author":"Weston","year":"2024","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.003_bib30","doi-asserted-by":"crossref","first-page":"e02255","DOI":"10.1128\/AAC.02255-19","article-title":"Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant, SME-producing Serratia marcescens","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.003_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime-taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.mcna.2025.01.003_bib32","first-page":"00499","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"S1473-3099","author":"Carmeli","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.003_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.003_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase-Producing pathogens in the CREDIBLE-CR and\u00a0APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib35","doi-asserted-by":"crossref","first-page":"e00159","DOI":"10.1128\/mBio.00159-19","article-title":"Targeting multidrug-resistant acinetobacter spp.: sulbactam and the diazabicyclooctenone \u03b2-lactamase inhibitor ETX2514 as a novel therapeutic agent","volume":"10","author":"Barnes","year":"2019","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.mcna.2025.01.003_bib36","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14787210.2018.1425139","article-title":"Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward \u201cmolecularly targeted\u201d therapy","volume":"16","author":"El Chakhtoura","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.003_bib39","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s15010-024-02371-1","article-title":"Ceftazidime-avibactam versus other antimicrobial agents for treatment of Multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis","volume":"52","author":"Gupta","year":"2024","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.003_bib40","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.003_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad152","article-title":"Activity of ceftolozane\/tazobactam, imipenem\/relebactam and ceftazidime\/avibactam against clinical Gram-negative isolates-SMART United States 2019-21","volume":"6","author":"Karlowsky","year":"2024","journal-title":"JAC-Antimicrob Resist"},{"issue":"24","key":"10.1016\/j.mcna.2025.01.003_bib42","first-page":"00648","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"S1473-3099","author":"Shields","year":"2024","journal-title":"Lancet Infect Dis"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T12:34:31Z","timestamp":1760790871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525000136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0025712525000136"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.01.003","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Severe Infections","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}